Egypt’s Sickle Cell disease market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Sickle cell disease is the most common inherited red blood cell disorder. In sickle cell disease, abnormal protein presence and red blood cells become hard, sticky, and resemble the C-shaped farming tool “sickle”. The infected sickle cells die early, causing a perpetual shortage of red blood cells, blocking the small blood vessels. This causes pain and other serious problems such as acute chest syndrome, stroke, infection, heart problems, and kidney problems.
An increase in research and innovative treatments for the disease are propelling the market for the disease forward. The closed Egyptian community in Siwa Oasis has a high frequency of Hb S carriers and so represents one of the targets of prevention programs to be implemented in Egypt in order to reduce the economic burden of health services for treating patients with sickle cell disease.
Growing cases of blood-related disorders will drive the sickle cell market in the forecast period. Abnormal hemoglobin S has caused increased gene mutation disorders. Further, family history with blood disorders will boost up the sickle cell disease market growth.
Moreover, the increase in immigration of the African population, high demand for regenerative therapies, and strong pipeline will boost up the global sickle cell disease market. However, the unavailability of drugs in rural areas, and high cost of treatment, and low healthcare expenditure in developing countries may hamper the global sickle cell disease market.